{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:18Z","timestamp":1791593838529,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009033","name":"NHS Blood and Transplant","doi-asserted-by":"publisher","award":["NHSBT Small Grant Award 2024-2025 for Health economic. Grant ref:148TRAN24"],"award-info":[{"award-number":["NHSBT Small Grant Award 2024-2025 for Health economic. Grant ref:148TRAN24"]}],"id":[{"id":"10.13039\/100009033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04780-1","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:04:38Z","timestamp":1772877878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Catherine","family":"Kimber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Javan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Dor\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Tsiachristas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Desborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Estcourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"4780_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, AL Baughman AL M, Wise M, Morgan OW. Population incidence of Guillain-Barr\u00e9syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123\u201333.","journal-title":"Neuroepidemiology"},{"key":"4780_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ene.12190","volume":"21","author":"M Mahdi-Rogers","year":"2014","unstructured":"Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21:28\u201333.","journal-title":"Eur J Neurol"},{"key":"4780_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401:1878\u201390.","journal-title":"Lancet"},{"key":"4780_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jdiacomp.2016.05.007","volume":"30","author":"V Bril","year":"2016","unstructured":"Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016;30:1401\u20137.","journal-title":"J Diabetes Complications"},{"key":"4780_CR5","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Reviews. 2012;12:CD002277. https:\/\/doi.org\/10.1002\/14651858.CD002277.pub4.","journal-title":"Cochrane Database Syst Reviews"},{"key":"4780_CR6","first-page":"CD010369","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MPT, Hughes RAC, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Reviews. 2017;1:CD010369.","journal-title":"Cochrane Database Syst Reviews"},{"key":"4780_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1526-0968.2000.004004275.x","volume":"4","author":"AP Batocchi","year":"2000","unstructured":"Batocchi AP, Evoli A, Dischino C, et al. Therapeutic apheresis in myasthenia gravis. Ther Apher. 2000;4:275\u20139.","journal-title":"Ther Apher"},{"key":"4780_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through inhibition of Fc receptor. Science. 2001;291:484\u20136.","journal-title":"Science"},{"issue":"2","key":"4780_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","volume":"38","author":"L Connelly-Smith","year":"2023","unstructured":"Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice \u2013 Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77\u2013278.","journal-title":"J Clin Apher"},{"issue":"12","key":"4780_CR10","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA van Doorn","year":"2023","unstructured":"van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome. Eur J Neurol. 2023;30(12):3646\u201374.","journal-title":"Eur J Neurol"},{"key":"4780_CR11","unstructured":"Guidelines on the Use of Therapeutic Apheresis in. Clinical Practice \u2013 Evidence-Based Approach from the Writing Committee of the American Society for Apheresis (ASFA): The Eighth Special Issue. https:\/\/www.ammtac.org\/docs\/articulos\/ASFA%202019%20guidelines.pdf"},{"key":"4780_CR12","unstructured":"Immunoglobulin database annual report London:MDAS. 2025. https:\/\/igd.mdsas.com\/wp-content\/uploads\/Igd_AnnualReport_202324.pdf. Updated 2025; Cited 2025 July."},{"key":"4780_CR13","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"4780_CR14","unstructured":"Covidence systematic review software. Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org"},{"key":"4780_CR15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"4780_CR16","unstructured":"GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from gradepro.org."},{"issue":"1","key":"4780_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51\u20139.","journal-title":"Evid Policy"},{"issue":"1","key":"4780_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","volume":"117","author":"A Alipour-Faz","year":"2017","unstructured":"Alipour-Faz A, Shojaei M, Peyvandi H, Ramzi D, Oroei M, Ghadiri F, Peyvandi M. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belgica. 2017;117(1):245\u20139.","journal-title":"Acta Neurol Belgica"},{"issue":"23","key":"4780_CR19","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"1","key":"4780_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1212\/WNL.46.1.100","volume":"46","author":"V Bril","year":"1996","unstructured":"Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology. 1996;46(1):100\u20133.","journal-title":"Neurology"},{"issue":"3","key":"4780_CR21","first-page":"263","volume":"19","author":"JR Chaudhuri","year":"2014","unstructured":"Chaudhuri JR, Alladi S, Rukmini Mridula K, Boddu DB, Rao MV, Hemanth C, et al. Clinical outcome of Guillain-barr\u00e9 syndrome with various treatment methods and cost effectiveness: A study from tertiary care Center in South India: Yashoda GBS registry. Neurol Asia. 2014;19(3):263\u201370.","journal-title":"Neurol Asia"},{"issue":"2","key":"4780_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000050777","volume":"46","author":"HC Diener","year":"2001","unstructured":"Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange and immune adsorption in Guillain-Barr\u00e9 syndrome. Eur Neurol. 2001;46(2):107\u20139.","journal-title":"Eur Neurol"},{"issue":"6","key":"4780_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6):838\u201345.","journal-title":"Ann Neurol"},{"issue":"6","key":"4780_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41(6):789\u201396.","journal-title":"Ann Neurol"},{"key":"4780_CR25","first-page":"203","volume":"41","author":"NA Haridy","year":"2023","unstructured":"Haridy NA, Shehab M, Khedr EM. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barr\u00e9 Syndrome: A double-blind, randomized clinical trial. Restor Neurol Neurosci. 2023;41:203\u201317.","journal-title":"Restor Neurol Neurosci"},{"key":"4780_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"RAC Hughes","year":"1997","unstructured":"Hughes RAC, Sandoglobin Guillain Barr\u00e9 Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Lancet. 1997;349:225\u201330.","journal-title":"Lancet"},{"issue":"2","key":"4780_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","volume":"14","author":"JF Liu","year":"2010","unstructured":"Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH, Gu Y. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Therapeutic Apheresis Dialysis. 2010;14(2):153\u201360.","journal-title":"Therapeutic Apheresis Dialysis"},{"issue":"6","key":"4780_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jca.21646","volume":"33","author":"A Maheshwari","year":"2018","unstructured":"Maheshwari A, Sharma RR, Prinja S, Hans R, Modi M, Sharma N, Marwaha N. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin. J Clin Apheresis. 2018;33(6):631\u20137.","journal-title":"J Clin Apheresis"},{"issue":"12","key":"4780_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J R\u00f8nager","year":"2001","unstructured":"R\u00f8nager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967\u201373.","journal-title":"Artif Organs"},{"issue":"17","key":"4780_CR30","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Mech\u00e9","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PIDG-BSG. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med. 1992;326(17):1123\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"4780_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/tme.12169","volume":"25","author":"Y Ye","year":"2015","unstructured":"Ye Y, Li SL, Li YJ. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome. Transfus Med. 2015;25(2):79\u201384.","journal-title":"Transfus Med"},{"issue":"3","key":"4780_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.transci.2005.07.010","volume":"33","author":"LH Zinman","year":"2005","unstructured":"Zinman LH, Sutton D, Ng E, et al. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apheres Sci. 2005;33(3):317\u201324.","journal-title":"Transfus Apheres Sci"},{"key":"4780_CR33","unstructured":"Australian New Zealand Clinical Trials Registry: Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney (Australia)., 2005 Identifier ACTRN12621000815864 Is therapeutic plasma exchange a better treatment than intravenous immunoglobulin in people with severe Guillain-Barre Syndrome (GBS)?. 2021;1. Available from https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=381758. Cited 28 Feb 2025."},{"key":"4780_CR34","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2021 October 21- Identifier NCT05114941; Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome (GBS-PRAISING); Available from https:\/\/clinicaltrials.gov\/study\/NCT05114941. Cited 28 Feb 2025."},{"key":"4780_CR35","unstructured":"Clinical Trials Registry India. New Delhi: database publisher (India). 2024 -. Identifier CTRI\/2024\/02\/0693206, Guillain-Barr\u00e9 Syndrome: Choosing the Best Treatment - Plasma Exchange vs. Immunoglobulin Therapy. 2024. Available from: http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=99172. Cited 07 May 2008."},{"key":"4780_CR36","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2007 July -. Identifier NCT00515450; Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis. 2006. Available from https:\/\/clinicaltrials.gov\/study\/NCT00515450. Cited 28 Feb 2025."},{"key":"4780_CR37","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2020 Aug 27-. Identifier NCT04550611, Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barr\u00e9 Syndrome. Available from https:\/\/clinicaltrials.gov\/study\/NCT04550611. Cited 28 Feb 2025."},{"key":"4780_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mus.24960","volume":"53","author":"JC Furlan","year":"2016","unstructured":"Furlan JC, Barth D, Barnett C, Bril V. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve. 2016;53:872\u201376.","journal-title":"Muscle Nerve"},{"key":"4780_CR39","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1212\/WNL.0000000000208162","volume":"102","author":"Z Siddiqi","year":"2024","unstructured":"Siddiqi Z, Genge A, Qi C, et al. Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003). Neurology. 2024;102:6900.","journal-title":"Neurology"},{"key":"4780_CR40","unstructured":"Efgartigimod for treating. generalised myasthenia gravis: a single technology appraisal. NICE single technology appraisal 2023: ID4003."},{"issue":"6","key":"4780_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18553\/jmcp.2024.30.6.517","volume":"30","author":"P-W Lien","year":"2024","unstructured":"Lien P-W, Joshi M, Tice JA, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti\u2013acetylcholine receptor antibody\u2013positive generalized myasthenia gravis. JMCP. 2024;30(6):517\u201327.","journal-title":"JMCP"},{"key":"4780_CR42","doi-asserted-by":"crossref","unstructured":"Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR. Treatment of Guillain-Barr\u00e9 syndrome: a cost\u2010effectiveness analysis. J Clin Apheresis. 1999;14(3):107\u201313.","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3"},{"key":"4780_CR43","first-page":"1","volume":"8","author":"G Blackhouse","year":"2010","unstructured":"Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resource Allocation. 2010;8:1\u20139.","journal-title":"Cost Eff Resource Allocation"},{"key":"4780_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40261-016-0401-3","volume":"36","author":"N Bamrungsawad","year":"2016","unstructured":"Bamrungsawad N, Upakdee N, Pratoomsoot C, et al. Economic evaluation of intravenous immunoglobulin plus corticosteroids for the treatment of steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy in Thailand. Clin Drug Investig. 2016;36:557\u201366.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"4780_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CND.0000000000000119","volume":"18","author":"P Ortiz-Salas","year":"2016","unstructured":"Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q, Jes\u00fas H. Human Immunoglobulin Versus Plasmapheresis in Guillain\u2013Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. J Clin Neuromuscul Dis. 2016;18(1):1\u201311.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"5","key":"4780_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/NRL.0000000000000342","volume":"26","author":"S Goudarzi","year":"2021","unstructured":"Goudarzi S, Esmaeeli S, Valencia JD, et al. Treatment Options for COVID-19-Related Guillain-Barr\u00e9 Syndrome: A Systematic Review of Literature. Neurologist. 2021;26(5):196\u2013224.","journal-title":"Neurologist"},{"key":"4780_CR47","first-page":"CD002063","volume":"2014","author":"RA Hughes","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2014;2014:CD002063.","journal-title":"Cochrane Database Syst Rev"},{"key":"4780_CR48","doi-asserted-by":"publisher","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","volume":"12","author":"TS Ipe","year":"2021","unstructured":"Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. Front Neurol. 2021;12:662856.","journal-title":"Front Neurol"},{"key":"4780_CR49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12913-021-07314-2","volume":"22","author":"T Kozul","year":"2022","unstructured":"Kozul T, Yudina A, Donovan C, et al. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions. BMC Health Serv Res. 2022;22:9.","journal-title":"BMC Health Serv Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04780-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:33:11Z","timestamp":1776169991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4780"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04780-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AT and JJ acknowledge funding support from the National Institute for Health and Care Research (NIHR) HealthTech Research Centre (HRC) Community Healthcare, and the NIHR Applied Research Collaboration (ARC) Oxford and Thames Valley. AT also acknowledges support from the NIHR Oxford Health Biomedical Research Centre. Funding received from NHSBT Small Grant Award. 2024 to \u201825\u202ffor Health economic. Grant Reference 148TRAN24. Systematic review including health economic assessment of the benefits of Intravenous immunoglobulin versus therapeutic apheresis for neurological conditions (the \u201cProject\u201d) \u00a373,659. No funders were involved with search, data collection, writing or decision to submit for publication. No funders were involved with search, data collection, writing or decision to submit for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}